Avantor increases manufacturing of single-use technology

By The Science Advisory Board staff writers

April 27, 2021 -- Avantor plans to increase its manufacturing capability of single-use technologies for biologics and vaccines.

The company will increase its capacity in the U.S. and Europe by 30% and double its cleanroom space to support demand for monoclonal antibodies, cell and gene therapies for oncology, and vaccines, including those for COVID-19.

The firm has already expanded its facility in Morrisville, NC, and will expand another in Devens, MA, by mid-year. It also plans to open a second European single-use technology manufacturing site, in Hillegom, the Netherlands.

Avantor to acquire liquid handling manufacturer Ritter for $1B
Avantor has entered into an agreement to acquire liquid handling consumables firm Ritter and its affiliates for approximately $1.05 billion in an...
Avantor expands its innovation center for bioprocessing
Avantor is increasing its investment in bioprocessing infrastructure by expanding its innovation center in Bridgewater, NJ.

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter